Author

M. A. Giardini

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1 Approach:statistical model· 1

Frequent Co-Authors

D. Skinner· 2 shared J. H. McKerrow· 2 shared J. L. Siqueira-Neto· 2 shared P. Fajtova· 2 shared A. Drelich· 1 shared A. E. Clark· 1 shared A. F. Carlin· 1 shared A. J. O'Donoghue· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

D. Skinner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2

L. H. Santos, T. Kronenberger, R. G. Almeida, E. Barbosa da Silva, R. E. O. Rocha, J. C. Oliveira, L. V. Barreto, D. Skinner, P. Fajtova, M. A. Giardini, B. Woodworth, C. Bardine, A. L. Lourenco, C. S. Craik, A. Poso, , R. Ferreira

This study identifies naphthoquinone derivatives as inhibitors of SARS-CoV-2 proteases Mpro and PLpro through virtual screening and biochemical assays.

bioRxiv · Jan 5, 2022Biochemistry

A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells

D. Mellott, C.-T. Tseng, A. Drelich, P. Fajtova, B. C. Chenna, D. Kostomiris, J. C. Hsu, J. Zhu, Z. Taylor, V. Tat, A. Katzfuss, L. Li, M. A. Giardini, D. Skinner, K. Hirata, , J. H. McKerrow

This paper shows that K777, a cysteine protease inhibitor, blocks SARS-CoV-2 infection by inhibiting host cathepsin L, which is required for spike protein processing, with nanomolar efficacy in several cell lines.

bioRxiv · Oct 23, 2020 · PreprintBiochemistry